Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.7 USD | -.--% | +4.94% | +11.11% |
Financials (USD)
Sales 2024 * | 24.2M | Sales 2025 * | 83.79M | Capitalization | 615M |
---|---|---|---|---|---|
Net income 2024 * | -200M | Net income 2025 * | -201M | EV / Sales 2024 * | 25.4 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 7.33 x |
P/E ratio 2024 * |
-2.22
x | P/E ratio 2025 * |
-2.48
x | Employees | 285 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.44% |
Latest transcript on Lexicon Pharmaceuticals, Inc.
1 week | +4.94% | ||
1 month | +10.39% | ||
3 months | -31.73% | ||
6 months | +60.38% | ||
Current year | +11.11% |
Managers | Title | Age | Since |
---|---|---|---|
Lonnel Coats
CEO | Chief Executive Officer | 58 | 14-07-06 |
Jeffrey Wade
DFI | Director of Finance/CFO | 59 | 98-12-31 |
Craig Granowitz
CTO | Chief Tech/Sci/R&D Officer | 60 | 21-08-01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Robert Lefkowitz
BRD | Director/Board Member | 80 | 01-01-31 |
Ray Debbane
CHM | Chairman | 69 | 07-07-31 |
Director/Board Member | 65 | 07-08-27 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 9 M€ | +9.86% | - | |
0.00% | 1,487 M€ | +7.77% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 1.7 | -.--% | 1,760,801 |
24-05-30 | 1.7 | +3.66% | 1,058,986 |
24-05-29 | 1.64 | -2.96% | 1,786,517 |
24-05-28 | 1.69 | +4.32% | 2,908,601 |
24-05-24 | 1.62 | +0.62% | 2,069,736 |
Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+11.11% | 615M | |
+11.91% | 118B | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.82% | 21.96B | |
-10.12% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B |
- Stock Market
- Equities
- LXRX Stock